The Patent Doc blog did a nice summary of recent articles speculating on which companies will have the greatest chance to be the first to successfully bring a biosimilar to market. Most observers think that some big players, who have the wherewithal to navigate IP and regulatory hurdles, as well as the financial strength, will be the first to prevail.
Companies mentioned from this category include Novartis' Sandoz unit, Pfizer, Merck, Teva, Hospira, and Stada.
Recent market studies by Global Industry Analysts and PharmaLive peg the biosimilar market to be worth $10 B by 2015 or 2017 respectively. Although, there is further acknowledgement that legislation regarding regulatory pathways and patent infringement could slow things down - and certainly introduce uncertainty which may affect investment.
Posted by Bruce Lehr September 24th 2010.
Comments